CD19 and acute lymphoblastic leukemia: Recent long-term follow-up data from 12 studies of CD19-targeted CAR-T therapy products in B-ALL patients (median follow-up 1–4.8 years) confirm excellent initial complete remission (CR) rates of 62%–86%, with most achieving deep MRD-negative remissions.